GC Pharma (Formerly known as Green Cross)
107, Ihyeon-ro 30beon-gil
26 articles with GC Pharma (Formerly known as Green Cross)
Profitability has improved Through International expansion
Profitability is expected to improve from Q2 and on
The Company Joins the Bleeding Disorder's Community to Celebrate
Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
Clinigen K.K. and GC Pharma announced an exclusive licensing agreement in Japan to commercialize Hunterase ICV, a human recombinant iduronate-2-sulfatase used in enzyme replacement therapy for the treatment of Hunter syndrome.
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2018.
CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome
CANbridge Pharmaceuticals Inc. announced an exclusive licensing agreement in the greater China area to commercialize Hunterase™, a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for the treatment of Hunter syndrome.
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months ended September 30, 2018.
GC Pharma Receives Korea's MFDS Approval of GCFLU Quadrivalent (Influenza Vaccine) for persons 6 months and older
GC Pharma announced today it has received approval from the South Korean Ministry of Food and Drug Safety (MFDS) expanding the indication for GCFLU Quadrivalent™ (Seasonal Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was approved for use in persons 3 years of age and older.
Q2 Performance was In-line with Expectations
GC Pharma announced unaudited results for the three months ended March 31, 2018.
GC Pharma and Lee's Pharm Enter Into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
Under the terms of the agreement, Lee's Pharm receives exclusive rights to develop and commercialise the anticoagulant for the greater China and South East Asian market.
GC Pharma (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2017.
The clinical 2/3 trial is expected to take around 5 years to complete, with patient enrollment beginning in early 2018.
President Of Leading South Korean Biopharmaceutical Company Green Cross Joins Stemedica Cell Technologies, Inc.'s Board Of Directors
Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
Green Cross Gains Market Approval With the World's 2nd Orphan Drug for Hunter Syndrome in South Korea